Current trends in pediatric aggressive B-cell lymphomas treatment
Nowadays due to modern risk-adapted treatment protocols high survival rates have been achieved in patients with aggressive B-cell lymphomas, even at stages III–IV these indicators overrun 90 %. Mainly these successes were associated with the inclusion of rituximab in the standard chemotherapy regime...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-06-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/471 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409286599344128 |
|---|---|
| author | Yu. S. Korkina T. T. Valiev |
| author_facet | Yu. S. Korkina T. T. Valiev |
| author_sort | Yu. S. Korkina |
| collection | DOAJ |
| description | Nowadays due to modern risk-adapted treatment protocols high survival rates have been achieved in patients with aggressive B-cell lymphomas, even at stages III–IV these indicators overrun 90 %. Mainly these successes were associated with the inclusion of rituximab in the standard chemotherapy regimens. As the follow up period of the patients is lengthened, it has become clear that ongoing treatment is associated with the development of immediate and long-term adverse effects of chemoimmunotherapy. In Russia and the world, there are multicenter studies aimed at studying prognostic factors that make it possible to reduce single and/or total doses of chemotherapy drugs, and therefore, to reduce chemotherapy toxicity. The obtained data allow considering the early complete antitumor effect (after 2 courses of therapy) as an advantage factor, so it is possible to reduce program chemoimmunotherapy intensity without reducing high patients survival rates. |
| format | Article |
| id | doaj-art-77ff796a2f03407d811c8ca2ac0087cb |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2021-06-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-77ff796a2f03407d811c8ca2ac0087cb2025-08-20T03:35:33ZrusABV-pressОнкогематология1818-83462413-40232021-06-01162212710.17650/1818-8346-2021-16-2-21-27386Current trends in pediatric aggressive B-cell lymphomas treatmentYu. S. Korkina0T. T. Valiev1Pediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaPediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaNowadays due to modern risk-adapted treatment protocols high survival rates have been achieved in patients with aggressive B-cell lymphomas, even at stages III–IV these indicators overrun 90 %. Mainly these successes were associated with the inclusion of rituximab in the standard chemotherapy regimens. As the follow up period of the patients is lengthened, it has become clear that ongoing treatment is associated with the development of immediate and long-term adverse effects of chemoimmunotherapy. In Russia and the world, there are multicenter studies aimed at studying prognostic factors that make it possible to reduce single and/or total doses of chemotherapy drugs, and therefore, to reduce chemotherapy toxicity. The obtained data allow considering the early complete antitumor effect (after 2 courses of therapy) as an advantage factor, so it is possible to reduce program chemoimmunotherapy intensity without reducing high patients survival rates.https://oncohematology.abvpress.ru/ongm/article/view/471burkitt lymphomadiffuse large b-cell lymphomaprimary mediastinal (thymic) large b-cell lymphomachemotherapyrituximabdose reductiontreatmentchildren |
| spellingShingle | Yu. S. Korkina T. T. Valiev Current trends in pediatric aggressive B-cell lymphomas treatment Онкогематология burkitt lymphoma diffuse large b-cell lymphoma primary mediastinal (thymic) large b-cell lymphoma chemotherapy rituximab dose reduction treatment children |
| title | Current trends in pediatric aggressive B-cell lymphomas treatment |
| title_full | Current trends in pediatric aggressive B-cell lymphomas treatment |
| title_fullStr | Current trends in pediatric aggressive B-cell lymphomas treatment |
| title_full_unstemmed | Current trends in pediatric aggressive B-cell lymphomas treatment |
| title_short | Current trends in pediatric aggressive B-cell lymphomas treatment |
| title_sort | current trends in pediatric aggressive b cell lymphomas treatment |
| topic | burkitt lymphoma diffuse large b-cell lymphoma primary mediastinal (thymic) large b-cell lymphoma chemotherapy rituximab dose reduction treatment children |
| url | https://oncohematology.abvpress.ru/ongm/article/view/471 |
| work_keys_str_mv | AT yuskorkina currenttrendsinpediatricaggressivebcelllymphomastreatment AT ttvaliev currenttrendsinpediatricaggressivebcelllymphomastreatment |